“A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma”. Cancer80 (1): 42–9. (July 1997). doi:10.1002/(SICI)1097-0142(19970701)80:1<42::AID-CNCR6>3.0.CO;2-H. PMID9210707.
“Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial”. Lancet356 (9232): 802–7. (September 2000). doi:10.1016/S0140-6736(00)02654-4. PMID11022927.
“Preclinical ex vivo expansion of G-CSF-mobilized peripheral blood stem cells: effects of serum-free media, cytokine combinations and chemotherapy”. Eur. J. Haematol.74 (2): 128–35. (February 2005). doi:10.1111/j.1600-0609.2004.00343.x. PMID15654904.
“Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up”. Eur. Urol.56 (2): 260–5. (August 2009). doi:10.1016/j.eururo.2009.04.009. PMID19395154.
“Treatment of vulvar intraepithelial neoplasia with topical imiquimod”. N. Engl. J. Med.358 (14): 1465–73. (April 2008). doi:10.1056/NEJMoa072685. PMID18385498.
“Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood”. Cancer Biol. Ther.8 (16): 1540–9. (August 2009). doi:10.4161/cbt.8.16.8950. PMID19471115.
“Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells”. J. Immunother.32 (6): 539–51. (2009). doi:10.1097/CJI.0b013e3181987c22. PMID19483655.
“Immunotherapy for the treatment of prostate cancer”. Nature Reviews Clinical Oncology8 (9): 551–61. (September 2011). doi:10.1038/nrclinonc.2011.72. PMID21606971.
“Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma”. J. Immunother.35 (8): 615–20. (October 2012). doi:10.1097/CJI.0b013e31826e8f5f. PMID22996367.
“Natural killer cells inhibit hepatitis C virus expression”. J. Leukoc. Biol.76 (6): 1171–9. (December 2004). doi:10.1189/jlb.0604372. PMID15339939.
“Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity”. J. Immunother.34 (2): 129–38. (March 2011). doi:10.1097/CJI.0b013e3182048c4e. PMID21304407.
“Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections”. Int. Rev. Immunol.27 (3): 93–110. (2008). doi:10.1080/08830180801911743. PMID18437601.
“alpha-Interferon treatment of patients with chronic fatigue syndrome”. Immunol. Invest.25 (1–2): 153–64. (1996). doi:10.3109/08820139609059298. PMID8675231.
“Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome”. Clin. Infect. Dis.18 Suppl 1: S157–9. (January 1994). doi:10.1093/clinids/18.Supplement_1.S157. PMID8148445.
“Killing of human Herpes virus 6-infected cells by lymphocytes cultured with interleukin-2 or -12”. Pediatr Int42 (6): 631–6. (December 2000). doi:10.1046/j.1442-200x.2000.01315.x. PMID11192519.
“The immune tolerance network: a new paradigm for developing tolerance-inducing therapies”. The Journal of Allergy and Clinical Immunology110 (1): 17–23. (July 2002). doi:10.1067/mai.2002.124258. PMID12110811.
“Association between parasite infection and immune responses in multiple sclerosis”. Annals of Neurology61 (2): 97–108. (February 2007). doi:10.1002/ana.21067. PMID17230481.
“An update on the use of helminths to treat Crohn's and other autoimmunune diseases”. Parasitol. Res.104 (2): 217–21. (January 2009). doi:10.1007/s00436-008-1297-5. PMID19050918.
“Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes”. Clin. Cancer Res.1 (5): 501–7. (May 1995). PMID9816009.
“A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma”. Cancer80 (1): 42–9. (July 1997). doi:10.1002/(SICI)1097-0142(19970701)80:1<42::AID-CNCR6>3.0.CO;2-H. PMID9210707.
“Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial”. Lancet356 (9232): 802–7. (September 2000). doi:10.1016/S0140-6736(00)02654-4. PMID11022927.
“Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial”. Clin. Cancer Res.8 (6): 1767–71. (June 2002). PMID12060615.
“Preclinical ex vivo expansion of G-CSF-mobilized peripheral blood stem cells: effects of serum-free media, cytokine combinations and chemotherapy”. Eur. J. Haematol.74 (2): 128–35. (February 2005). doi:10.1111/j.1600-0609.2004.00343.x. PMID15654904.
“Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up”. Eur. Urol.56 (2): 260–5. (August 2009). doi:10.1016/j.eururo.2009.04.009. PMID19395154.
“Treatment of vulvar intraepithelial neoplasia with topical imiquimod”. N. Engl. J. Med.358 (14): 1465–73. (April 2008). doi:10.1056/NEJMoa072685. PMID18385498.
“Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood”. Cancer Biol. Ther.8 (16): 1540–9. (August 2009). doi:10.4161/cbt.8.16.8950. PMID19471115.
“Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells”. J. Immunother.32 (6): 539–51. (2009). doi:10.1097/CJI.0b013e3181987c22. PMID19483655.
“Immunotherapy for the treatment of prostate cancer”. Nature Reviews Clinical Oncology8 (9): 551–61. (September 2011). doi:10.1038/nrclinonc.2011.72. PMID21606971.
“Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma”. J. Immunother.35 (8): 615–20. (October 2012). doi:10.1097/CJI.0b013e31826e8f5f. PMID22996367.
“Natural killer cells inhibit hepatitis C virus expression”. J. Leukoc. Biol.76 (6): 1171–9. (December 2004). doi:10.1189/jlb.0604372. PMID15339939.
“Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity”. J. Immunother.34 (2): 129–38. (March 2011). doi:10.1097/CJI.0b013e3182048c4e. PMID21304407.
“Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections”. Int. Rev. Immunol.27 (3): 93–110. (2008). doi:10.1080/08830180801911743. PMID18437601.
“alpha-Interferon treatment of patients with chronic fatigue syndrome”. Immunol. Invest.25 (1–2): 153–64. (1996). doi:10.3109/08820139609059298. PMID8675231.
“Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome”. Clin. Infect. Dis.18 Suppl 1: S157–9. (January 1994). doi:10.1093/clinids/18.Supplement_1.S157. PMID8148445.
“Killing of human Herpes virus 6-infected cells by lymphocytes cultured with interleukin-2 or -12”. Pediatr Int42 (6): 631–6. (December 2000). doi:10.1046/j.1442-200x.2000.01315.x. PMID11192519.
“The immune tolerance network: a new paradigm for developing tolerance-inducing therapies”. The Journal of Allergy and Clinical Immunology110 (1): 17–23. (July 2002). doi:10.1067/mai.2002.124258. PMID12110811.
“Association between parasite infection and immune responses in multiple sclerosis”. Annals of Neurology61 (2): 97–108. (February 2007). doi:10.1002/ana.21067. PMID17230481.
“An update on the use of helminths to treat Crohn's and other autoimmunune diseases”. Parasitol. Res.104 (2): 217–21. (January 2009). doi:10.1007/s00436-008-1297-5. PMID19050918.